23andMe Holding is engaged in developing direct-to-consumer precision medicine platform and a portfolio of genetically validated therapeutic candidates for various diseases across different therapeutic areas. Co.'s segments are: Consumer and Research Services, which provides its Personal Genome Service® telehealth business and research services; and Therapeutics, which focuses on the use of genetic insights from its database of genetic and phenotypic information to develop therapies and consists of out-licensing of intellectual property associated with identified drug targets and activities related to therapeutic product candidates.